D 519927

Drug Profile

D 519927

Latest Information Update: 28 Dec 2000

Price : $50

At a glance

  • Originator Daiichi Pharmaceutical
  • Class Antiulcers
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Peptic ulcer

Most Recent Events

  • 28 Dec 2000 Discontinued-Preclinical for Peptic ulcer in Japan (Unknown route)
  • 09 Oct 1997 New profile
  • 09 Oct 1997 Preclinical development for Peptic ulcer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top